OrthoPediatrics (NASDAQ:KIDS) Sees Strong Trading Volume – Here’s What Happened

Posted by George Bondi on Aug 28th, 2026

OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) saw unusually-high trading volume on Friday . 379,983 shares changed hands during mid-day trading, an increase of 122% from the previous session’s volume of 171,488 shares.The stock last traded at $23.61 and had previously closed at $23.32.

Wall Street Analyst Weigh In

KIDS has been the subject of a number of research reports. Piper Sandler reiterated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Truist Financial set a $22.00 target price on OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC upped their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average price target of $26.44.

Read Our Latest Stock Analysis on KIDS

OrthoPediatrics Trading Up 2.1%

The firm has a market capitalization of $621.68 million, a PE ratio of -14.17 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The company’s 50-day simple moving average is $21.32 and its 200 day simple moving average is $18.62.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, sell-side analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Insider Buying and Selling

In other OrthoPediatrics news, Director David R. Pelizzon sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the transaction, the director owned 6,863,464 shares in the company, valued at approximately $166,644,905.92. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Jennifer N. Pritzker sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the sale, the insider owned 6,863,464 shares in the company, valued at $166,644,905.92. This trade represents a 0.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 114,900 shares of company stock valued at $2,829,906. Corporate insiders own 32.50% of the company’s stock.

Institutional Trading of OrthoPediatrics

Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after buying an additional 645 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of OrthoPediatrics in the second quarter worth approximately $34,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.